Anika Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Anika Therapeutics, Inc. has issued its proxy statement for the upcoming Annual Meeting of Stockholders on June 18, 2026, detailing proposals including director elections, auditor ratification, executive compensation approval, and amendments to equity incentive and employee stock purchase plans.
NASDAQ
Anika Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
NASDAQ
DEF: Anika Therapeutics Seeks Stockholder Approval for Incentive Plan Amendment to Fuel Growth Strategy
Anika Therapeutics is asking stockholders to approve an amendment to its 2017 Omnibus Incentive Plan to increase the number of authorized shares, aiming to attract and retain key talent for its growth strategy.
NASDAQ
Anika Therapeutics issues a statement disagreeing with Glass Lewis's recommendation against the election of director Stephen O. Richard, asserting his independence and urging stockholders to vote in his favor.
NASDAQ
Anika Therapeutics is focusing on profitable growth and expects over 75% adjusted EBITDA growth in 2024 through strategic spending cuts and product portfolio optimization.